Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

- Approval of Second IND Marks Major Corporate Milestone and Advances

Clinical Program -

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is repurposing for the treatment of endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina recently completed a global licensing agreement to make, develop and commercialize products, including MPI-676, under AstraZeneca's IP and know-how regarding the use of AIs in combination with estrogen and progestin to treat endometriosis.

"This IND for MPI-676 marks another major milestone in our robust clinical program focused on addressing women's reproductive system disorders," said James Symons, Ph.D., Vice President, Clinical Development, Meditrina Pharmaceuticals, Inc. "Based on the encouraging proof of concept and strong safety data established for MPI-676, we look forward to selecting the dose for Phase III pivotal trials, which will be at a dose lower than for which AstraZeneca has already established two-year chronic use safety data in their breast cancer prevention trials and is cited in the anastrozole product label. These data will advance development of MPI-676 and help us bring this important new treatment to women suffering from endometriosis, a painful and debilitating condition."

This US-based, multi-center, placebo-controlled, double-blinded study will identify the maximally efficacious dose of MPI-676 to investigate in the pivotal Phase III program. The Phase IIb dose ra
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014 /PRNewswire/ ... operates in Southern California , today ... caregiving technology. Alta will be providing the innovative BeClose ... services. Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... to providing the kind of affordable 24/7 care our ...
(Date:11/21/2014)... Nov. 21, 2014  World Hemp Oil, an importer ... announces they are now offering legal, organic oil with ... type strains grown in medical marijuana states. People suffering ... such as Parkinson,s, MS, and spinal cord injury, no ... pass, because imported CBD Oil Is legal in all ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... ECRI Institute ®, an independent nonprofit that researches the ... of PriceGuide 4.0 , the latest generation of ... medical-surgical supplies and implants.   (Logo: ... a whole new level of interactivity and functionality for ...
... We applaud Gov. Rick Snyder for his efforts to put ... As the Governor stated, "the state of Michigan currently ... of 31.7 percent." It also has the sixth-highest rate of ... high rates of chronic conditions, Michiganders also appear to suffer ...
Cached Medicine Technology:New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 2New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 3Statement from the Michigan Society of Anesthesiologists in Response to Governor Snyder's Health & Wellness Announcement 2
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader ... 2014 Evening Dresses. All these fresh items are offered ... manager, the special offer is valid until Dec. 20, ... has been working well in the fashion industry for ... Their new dresses may be the best products for ...
(Date:11/24/2014)... Mental health issues affect tens of ... families, ruin careers, and generally destroy lives. , ... suffer,” says Hardy Nutritionals® founder David ... specialized nutritional treatments can reverse these disorders naturally.” ... Matter”, the premiere episode of O2 Media’s new ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 "My friend ... was trying to cross the street in his motorized ... never saw him. I came up with this idea ... at night." , He developed the Safety Lites to ... in low-lighting conditions. The device ensures that motorists can ...
(Date:11/23/2014)... the coming special Friday, Tidebuy, a famous wedding dress ... many products, especially the beautiful colored wedding dresses ( ... amazing discounts, up to 90% off. Don’t hesitate to ... to buy colored wedding dresses in different sizes and ... for delicate craftsmanship, elegant style and perfect lines. All ...
Breaking Medicine News(10 mins):Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2
... U.S. have continued to be mild, officials said , , ... Organization on Wednesday raised the swine flu epidemic level ... imminent, and urged countries to implement their pandemic plans. ... officials that the outbreak could trigger large numbers of ...
... Ohio Residents Access to Nursing Home, Assisted Living, Home Care ... Code StatewideRICHMOND, Va., April 30 The cost ... rate outpacing inflation, putting significant financial pressure on those in ... Financial. At the same time, the current economic downturn ...
... Nursing Home, Assisted Living, Home Care and Adult Day Health ... 30 The cost of long ... outpacing inflation, putting significant financial pressure on those in or ... At the same time, the current economic downturn has led ...
... Mexico Residents Access to Nursing Home, Assisted Living, ... Every Zip Code Statewide RICHMOND, Va., April 30 ... is rising at a rate outpacing inflation, putting significant financial ... annual study by Genworth Financial. At the same time, ...
... Residents Access to Nursing Home, Assisted Living, Home Care and ... StatewideRICHMOND, Va., April 30 /PRNewswire/ -- ... at a rate outpacing inflation, putting significant financial pressure on ... by Genworth Financial. At the same time, the current ...
... Assisted Living, Home Care and Adult Day Health Care Costs ... /PRNewswire/ -- The cost of long term ... inflation, putting significant financial pressure on those in or near ... At the same time, the current economic downturn has led ...
Cached Medicine News:Health News:WHO Raises Swine Flu Alert 2Health News:WHO Raises Swine Flu Alert 3Health News:WHO Raises Swine Flu Alert 4Health News:WHO Raises Swine Flu Alert 5Health News:WHO Raises Swine Flu Alert 6Health News:Growth in Ohio Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Ohio Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Ohio Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in North Carolina Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in North Carolina Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in North Carolina Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in North Carolina Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 5Health News:Growth in New Mexico Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in New Mexico Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in New Mexico Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Nevada Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Nevada Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Nevada Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Long Term Care Costs in New Jersey Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Long Term Care Costs in New Jersey Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Long Term Care Costs in New Jersey Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: